• LivaNova raised its 2026 constant-currency revenue growth forecast to 9%-10% from 8%-9% on November 4.
• Adjusted diluted earnings guidance increased to $4.40-$4.50 per share from $4.30-$4.40.
• Adjusted operating margin guidance remained 20%-21%; adjusted free cash flow is still forecast at $140 million-$160 million.
• The outlook follows third-quarter revenue of $393.1 million, up 10% in constant currencies, driven by Cardiopulmonary and Epilepsy demand.
• Capital spending remains projected at $135 million to support innovation, growth and IT infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.